Vitalhub (VHI) Q2 2024 earnings summary

Executive summary

• Achieved strong revenue and profitability growth in Q2 2024 and the first half of the year, driven by organic expansion and acquisitions.

• Q2 2024 revenue rose 24% year-over-year to CAD 16.2M, with ARR up 25% to CAD 51.3M.

• Adjusted EBITDA increased 41% year-over-year to CAD 4.2M, representing 26% of revenue.

• Net income before tax in Q2 was CAD 1.4M (up 86%); H1 was CAD 3.4M (up 121%).

• Announced acquisition of MedCurrent Corporation to enhance clinical decision support capabilities.

Financial highlights

• Q2 2024 revenue was CAD 16.2M, up 24% year-over-year; H1 2024 revenue was CAD 31.5M, up 23%.

• Term licenses, maintenance, and support revenue grew 28% in Q2 and 26% in H1, now 80% of total revenue.

• Professional services and hardware revenue rose 21% in Q2 and 19% in H1.

• Gross margin remained strong at 81% for both Q2 and H1.

• Cash on hand at June 30, 2024, was CAD 71.6M, up from CAD 33.5M at year-end, mainly due to a CAD 37M/$40.3M bought deal and operational cash flow.

Outlook and guidance

• Expect continued execution on recurring revenue model and backlog fulfillment.

• Anticipate MedCurrent acquisition to close in September, with more acquisitions likely by year-end.

• Management expects continued growth through operational excellence and disciplined cash management.

• Focus remains on innovation, customer value, and expanding market leadership in healthcare technology.

• Cautious optimism about pipeline defensibility in government-focused healthcare IT, though some seasonality and variability are expected.